Biliary Tract Cancer Clinical Trial Landscape

The biliary tract cancer trial landscape in 2026

Biliary tract cancers — encompassing intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), perihilar cholangiocarcinoma, and gallbladder cancer — have undergone a rapid clinical development transformation. For decades, gemcitabine plus cisplatin was the only standard of care. The TOPAZ-1 trial (durvalumab + GemCis) changed that, and the field has not slowed since.

In 2026, BTC is one of oncology's most active targeted therapy arenas. HER2 overexpression in approximately 15–20% of biliary tract cancers has created a competitive race among ADC and bispecific programs. FGFR2 fusions in intrahepatic cholangiocarcinoma have generated approved targeted therapies (pemigatinib, futibatinib, infigratinib). IDH1 mutations in iCCA have ivosidenib as an approved agent. The pipeline is layered and molecularly stratified in a way that makes competitive intelligence essential.

Key mechanisms active in BTC clinical development in 2026:

• HER2-targeted ADCs: Trastuzumab deruxtecan (T-DXd, AstraZeneca) in Phase 3 against HER2-expressing BTC — the DESTINY-PanTumor data in HER2+ solid tumors has accelerated BTC-specific Phase 3 registration
• HER2 bispecifics: Zanidatamab (Jazz/Zymeworks) in Phase 3 vs. standard of care in HER2-positive BTC — the HERIZON-BTC-01 trial testing a bispecific HER2 antibody head-to-head against SoC
• Checkpoint + chemotherapy: AstraZeneca's ARTEMIDE-Biliary02 Phase 3 testing rilvegostomig (PD-1/TIM-3 bispecific) or durvalumab combined with chemotherapy in first-line BTC
• Novel checkpoint approaches: Rilvegostomig (anti-PD-1/TIM-3 bispecific) is AstraZeneca's next-generation immunotherapy asset — simultaneous PD-1 and TIM-3 blockade in a single molecule
• Early-phase ADCs: Multiple Phase 1/2 programs from AstraZeneca (AZD8205), SystImmune (BL-M07D1), and Alentis Therapeutics targeting BTC as part of basket or tumor-agnostic designs

Current BTC trial activity (as of early 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

AstraZeneca is the dominant sponsor in biliary tract cancer in 2026 — the company has at least five active BTC-relevant trials covering first-line checkpoint combinations, HER2-directed ADCs, and real-world evidence. The three Phase 3 trials all have industry sponsors and represent distinct molecular hypotheses: checkpoint in all-comers (ARTEMIDE-Biliary02), HER2-targeted ADC (T-DXd + rilvegostomig), and HER2 bispecific antibody (zanidatamab). Winning even one of these could establish a new standard of care in HER2+ BTC, a molecularly defined population with no currently approved targeted therapy despite high prevalence.

The BTC competitive landscape in 2026

Why biliary tract cancer is an emerging oncology priority

Biliary tract cancers carry a poor prognosis — median overall survival in first-line advanced BTC remains approximately 12–15 months even with checkpoint immunotherapy added to chemotherapy. That unmet need, combined with the identification of actionable molecular targets in substantial patient subpopulations, has attracted major oncology sponsors. HER2 overexpression (15–20% of BTC), FGFR2 fusions (~15% of iCCA), and IDH1 mutations (~20% of iCCA) mean that a significant fraction of patients can potentially be matched to targeted therapies.

The HER2 race in biliary tract cancer

No HER2-targeted therapy is currently approved specifically for biliary tract cancer, despite the well-characterized prevalence of HER2 overexpression. The two Phase 3 trials running in 2026 represent competing molecular strategies in the same HER2+ BTC patient population. AstraZeneca is betting on T-DXd — the same ADC approved across multiple HER2+ tumor types — combined with its novel rilvegostomig bispecific. Jazz Pharmaceuticals (via its Zymeworks acquisition) is testing zanidatamab, a bispecific HER2 antibody targeting two distinct HER2 epitopes simultaneously. For BD teams and oncology analysts, the HER2+ BTC race is one of the clearest competitive intelligence scenarios in oncology in 2026.

Rilvegostomig: AstraZeneca's bispecific checkpoint bet

Rilvegostomig (AZD7789) is a bispecific antibody simultaneously blocking PD-1 and TIM-3, two immune checkpoint receptors with potentially complementary mechanisms. AstraZeneca has positioned it as a next-generation checkpoint agent across multiple tumor types, and BTC is one of two Phase 3 studies it is running in BTC in 2026 — one as monotherapy versus durvalumab in first-line (ARTEMIDE-Biliary02), and one combined with T-DXd in HER2+ BTC. The breadth of AstraZeneca's BTC investment is unusual and reflects the company's view that BTC is a commercially significant indication where it can establish multiple lines of competitive advantage.

FGFR and IDH1: the earlier wave

The FGFR2 inhibitor wave (pemigatinib, futibatinib) and IDH1 inhibitor approvals (ivosidenib) preceded the current HER2 race. While those agents are approved, academic and biomarker studies continue in 2026 — including an ivosidenib maintenance study (NCT07260175) and ongoing ctDNA and biomarker correlation studies in IDH1-mutant cholangiocarcinoma. For molecular intelligence, these studies provide early data on resistance mechanisms and combination opportunities in an already-approved patient population.

What DataLookout monitors for biliary tract cancer

Configure your profile with condition and mechanism keywords for targeted BTC monitoring:

• Condition terms: "biliary tract cancer", "cholangiocarcinoma", "intrahepatic cholangiocarcinoma", "iCCA", "BTC", "gallbladder cancer", "bile duct cancer"
• By molecular subtype: "HER2 biliary", "FGFR2 cholangiocarcinoma", "IDH1 cholangiocarcinoma", "HER2-positive BTC"
• By mechanism: "ADC biliary", "checkpoint biliary", "trastuzumab deruxtecan", "zanidatamab", "rilvegostomig", "FGFR inhibitor"
• By sponsor: Monitor specific company programs — enter "AstraZeneca cholangiocarcinoma" or "Jazz biliary" for sponsor-specific competitive intelligence
• By phase: Filter to Phase 3 BTC trials only for pivotal study tracking; Phase 1/2 for early pipeline intelligence

Who uses BTC trial monitoring

Oncology business development teams

BD professionals at pharma and biotech companies tracking biliary tract cancer watch competitor Phase 2 registrations daily. In a molecularly stratified indication like BTC, a new Phase 1/2 trial targeting a specific biomarker subset signals a potential licensing target or competitive threat years before any readout. The current three-way Phase 3 race in HER2+ BTC means new BD decisions are being shaped by trial registration activity today.

Oncology portfolio analysts and healthcare investors

BTC is a high-stakes indication for AstraZeneca's immuno-oncology portfolio. T-DXd and rilvegostomig both have BTC as Phase 3 programs — registration-enabling milestones that will drive significant stock and valuation events. Trial status changes, enrollment completion events, and study amendments appear in ClinicalTrials.gov before press releases. DataLookout surfaces these signals in your daily digest.

Medical affairs at BTC-active companies

Medical affairs teams at companies with BTC programs monitor the competitive landscape for KOL publication activity, emerging biomarker data, and new Phase 2 registrations. The number of academic ctDNA and biomarker studies in advanced BTC reflects growing KOL engagement — valuable signal for conference planning and advisory board strategy.

Frequently asked questions